ENTITY
YiChang HEC ChangJiang Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical (1558 HK)

137
Analysis
Health Care • China
YiChang HEC ChangJiang Pharmaceutical develops, manufactures, and sells pharmaceutical products, focusing on anti-viral, endocrine and metabolic, and cardiovascular diseases. Key products include Kewei (oseltamivir phosphate), Oumeining (telmisartan), and Ertongshu (benzbromarone). The company was founded in 2001 and is headquartered in Dongguan, China.
more
•08 May 2020 10:04

Hong Kong Buyback League Table: Evergrande, Yichang HEC, Yanzhou Coal

Hong Kong Exchange publishes share repurchases by listed companies on a daily basis. In our weekly note, we will provide statistics on top...

Logo
459 Views
Share
•20 Jan 2020 09:33

Hong Kong Buyback Weekly: Xingyi Glass, Yichang HEC, Consun Pharma

Hong Kong Exchange publishes share repurchases by listed companies on a daily basis. In our weekly note, we will provide statistics on top...

Logo
489 Views
Share
•25 Nov 2019 14:40

Hong Kong Buyback Weekly: Yichang HEC, Weimob and China Literature

In the past 7 days, the top 3 companies that repurchased the most shares from the market were Yichang Hec Changjiang Pharm (1558 HK) (HKD 42.3...

Logo
492 Views
Share
bullish•Meituan
•18 Nov 2019 22:40

HK Connect Flows: Close Meituan/Elong Trade with a 14.5% Profit

In our weekly HK Connect Flow series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed...

Logo
450 Views
Share
•18 Nov 2019 10:33

Hong Kong Buyback Weekly: Yichang HEC, Viva Biotech, China Literature Led the Buybacks

In the past 7 days, the top 3 companies that repurchased the most shares from the market were Yichang Hec Changjiang Pharmaceutical Co., Ltd. (1558...

Logo
411 Views
Share
x